A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study
comparing 3 mg/kg of AIN457 to placebo. Subjects with a diagnosis of moderate to severe
stable plaque psoriasis will be randomized to receive either AIN457 or placebo. AIN457 or
placebo will be administered by single infusion at baseline and subjects will be observed for
up to 26 weeks following the infusion.